Correct - there are only a handful left to clear - not totally...

Correct - there are only a handful left to clear - not totally unexpected given the market conditions and given the IPO went to some of the "wrong hands" (not ppl interested in the potential of the company/experienced in biotech) then missed the unrealistic expectations pitched to them (combo of market conditions and some other factors). Top 50 is now up to ~70m/70%+ & what's becoming a tight register to build an Market cap more reflective of the potential & progress to date. I expect a material rerate (to the upside) to something more sensible shortly.

Via http://sprout8.com/rhy-research-report/

"We have reviewed the top 50 as at the 26th of April 2018 and the directors holdings have remained consistent. We note some additional holders on the Top 20 of the register since the IPO.

• CitiCorp Nominees – 2,170,000
• Brispot Nominees – 1,610,031
• Alitime Nominees – 1,220,000

The following have increased since the top 20 as at December 2017, published herehttps://www.rhythmbio.com/wp-conten...Biosciences-Replacement-Prospectus-301017.pdf:

• Northern Star Nominees +100,000
• Mrs Sarah Cameron +350,000
• Giokir – +375,000
• CS Fourth Nominees +468,347
• Mr Gregory Maurice Pinkus & Mrs Lisa Marie Pinkus +250,000

The following holders appear to be reducing or exiting:

• Merrill Lynch (Australia) Nominees – 221,579 units remain versus 1550000 in the IPO
• CS Third Nominees – have decreased their holding by -398,231 units
• Morgan Stanley Australia Securities (Nominee) – Have reduced -13,072 units
• Aust Executor Trustees – have exited from 1,500,000 to nil"

Cheers

5x8's